argenx to Report Full Year 2021 Financial Results and Fourth Quarter Business Update on March 3, 2022
24 Février 2022 - 07:00AM
February 24, 2022Breda,
the Netherlands – argenx (Euronext & Nasdaq: ARGX), a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases, today announced
that it will host a conference call and audio webcast on Thursday,
March 3, 2022 at 2:30 pm CET (8:30 am ET) to discuss its full year
2021 financial results and provide a fourth quarter business
update.
A webcast of the live call may be accessed on
the Investors section of the argenx website at
argenx.com/investors. A replay of the webcast will be available on
the argenx website for approximately one year following the
call.
Dial-in numbers:
Please dial in 15 minutes prior to the live
call.
Belgium 32
800 50
201France 33
800
943355Netherlands 31
20 795 1090United
Kingdom 44 800 358
0970United States
1
888 415
4250Japan 81
3 4578
9752Switzerland 41
43 210 11 32
About argenx
argenx is a global immunology company committed
to improving the lives of people suffering from severe autoimmune
diseases. Partnering with leading academic researchers through its
Immunology Innovation Program (IIP), argenx aims to translate
immunology breakthroughs into a world-class portfolio of novel
antibody-based medicines. argenx developed and is commercializing
the first-and-only approved neonatal Fc receptor (FcRn) blocker in
the U.S. and Japan. The Company is evaluating efgartigimod in
multiple serious autoimmune diseases and advancing several earlier
stage experimental medicines within its therapeutic franchises. For
more information, visit www.argenx.com and follow us
on LinkedIn, Twitter, and Instagram.
For further information, please contact:
Media:
Kelsey Kirkkkirk@argenx.com
Joke Comijn (EU)jcomijn@argenx.com
Investors:
Beth DelGiaccobdelgiacco@argenx.com
Michelle Greenblattmgreenblatt@argenx.com
Argen X (EU:ARGX)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Argen X (EU:ARGX)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024